AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02303379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pyramid Training
Description: One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
Study NCT02303379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyramid Training
Description: One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
Study NCT02303379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
Study NCT02303379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
Study NCT02979665 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab Ophthalmic
Description: Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME).
Study NCT01526902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A / PC 1-D MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
Study NCT01526902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B / Air Optix MF
Description: Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
Study NCT04077658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartMath
Description: HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
Study NCT04077658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath
Description: HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
Study NCT04077658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Standard of Care Migraine Treatment
Study NCT02859935 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Screening and feedback
Description: Screening via questionnaires on mental health problems and feedback on the questionnaires
Study NCT05244265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).
Study NCT05244265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Different interventions and support in outpatient and other services.
Study NCT00812214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg tablet every night at bedtime
Study NCT00812214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet every night at bedtime
Study NCT01069562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional control
Description: The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
Study NCT01069562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop control
Description: The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
Study NCT02482454 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance
Study NCT02482454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance
Study NCT02482454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study NCT02716610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 69 U (low)
Description: inhaled human insulin
Study NCT02716610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 69 U (high)
Description: inhaled human insulin
Study NCT02716610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 139 U
Description: inhaled human insulin
Study NCT02716610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH 208 U
Description: inhaled human insulin
Study NCT02716610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIS 18 U
Description: subcutaneous insulin lispro
Study NCT04451915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late management strategy
Description: late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
Study NCT04451915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early management strategy
Description: early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
Study NCT04019132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
Study NCT04693000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
Description: An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Study NCT01656031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Study NCT01656031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00782457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RECTAL CANCER RESECTION
Study NCT00782457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RECTAL CANCER RESECTION
Study NCT03673683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SANDWICH protocol
Description: A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
Study NCT03673683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual sedation and weaning management that is not protocol based
Study NCT02944630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy
Study NCT02492503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and carboplatin
Description: Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
Study NCT02492503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and carboplatin
Description: Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
Study NCT02074852 — intervention group
Intervention type: OTHER
Intervention: Foley urethral catheter
Study NCT02684214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus +
Description: Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
Study NCT02684214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus -
Description: This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
Study NCT00951730 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
Study NCT04623242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Subcutaneously every 4 weeks at escalating doses
Study NCT04623242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Intravenous infusion every 4 weeks at escalating doses
Study NCT04623242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Gantenerumab)
Description: Subcutaneous injection of placebo every 4 weeks
Study NCT04623242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Solanezumab)
Description: Intravenous infusion of placebo every 4 weeks
Study NCT04325542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HBSAg (sure screen test)
Description: Diagnostic test for Hepatitis B
Study NCT01125280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment versus surgical treatment
Description: Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
Study NCT03770065 — intervention group
Intervention type: DEVICE
Intervention: VML-0001
Description: Medical device
Study NCT02326805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02326805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02326805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given SC
Study NCT02326805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilimogene Galvacirepvec
Description: Given SC
Study NCT03300466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP0045
Description: Hyaluronic acid gel
Study NCT03300466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Hyaluronic acid gel
Study NCT02897895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: levels of CNI in whole blood
Study NCT02897895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: levels of CNI in whole blood
Study NCT02897895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)
Study NCT03343132 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard locomotor therapy
Description: Typical clinical therapy.
Study NCT02797236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine
Study NCT02797236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine + adjuvant
Study NCT02797236 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02797236 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + adjuvant
Study NCT03847987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase I Capsule
Description: Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
Study NCT03847987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase II Tablet Unflavored
Description: Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
Study NCT03847987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase II Tablet Sweetened/Flavored
Description: Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
Study NCT03960281 — intervention group
Intervention type: OTHER
Intervention: Regular dental examination
Description: Regular dental examination, and the patient will be asked to fill a questionnaire
Study NCT02472132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC US
Description: Use of point of care ultrasound in insertion of CVC
Study NCT04222595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluenz Tetra nasal spray suspension
Description: Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
Study NCT03824860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~* guided breathing exercises,~* upper and lower extremity stretching~* structured postures and movements to improve balance and strength
Study NCT01858181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ocaratuzumab
Study NCT03253146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VIM detection
Description: VIM expression in serum and lymphocytes detection
Study NCT04312009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan; 50 mg daily; oral administration
Study NCT04312009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
Study NCT03146572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
Study NCT03146572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Handout providing written descriptions of strategies to encourage positive parenting behaviors
Study NCT00179309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
Study NCT00179309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-V
Description: 2 x 10\^8 PFU
Study NCT00179309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-F
Description: 1 x 10\^9 PFU
Study NCT00179309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
Study NCT03714945 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is required as this study is observational.
Study NCT01902966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
Study NCT01902966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary
Description: Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
Study NCT01902966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Audio Recording
Description: Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
Study NCT01902966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 2 months, and 4 months.
Study NCT02777216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ConfidenHT system
Description: ConfidenHT Medical system
Study NCT03044340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impedance measurement and pain evaluation
Description: Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
Study NCT01262521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 150 ml tab water with 150 umol/kg sodium-nitrate
Study NCT01262521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 150 ml Chapelle mineral water
Study NCT02868242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily
Study NCT00719927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comadres Weight Loss Pilot Program
Description: The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
Study NCT00719927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comadres Weight Loss Pilot Program
Description: The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
Study NCT02098174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-3180
Description: MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT02098174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iohexol comparator
Description: Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study NCT03193398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-246040 oral capsule(s)
Description: BTRX-246040 administered once daily to patients with MDD for 8 weeks
Study NCT03193398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule(s)
Description: administered once daily to patients with MDD for 8 weeks